Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis

Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis

Abstract Background In recent years, triple therapy (molecular targeted agent + PD-1 inhibitor + transarterial therapy) has emerged as a promising strategy for unresectable hepatocellular carcinoma (uHCC). However, the optimal molecular targeted agent choice within triple therapy remains unclear. Do...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaohong Wen, Shuyi Zhou, Yuyan Xu, Cheng Zhang, Zhoubin Feng, Yinghui Song, Bai Ding, Chuang Peng, Hongkun Tan, Chunming Wang, Jianan Feng, Jingyuan Pei, Guolin He, Shunjun Fu, Lvhuan Wang, Lei Cai, Sulai Liu, Mingxin Pan
Format: Article
Language:English
Published: BMC 2025-04-01
Series:World Journal of Surgical Oncology
Subjects:
Hepatocellular carcinoma
Molecular targeted agent
Transarterial therapy
PD-1 inhibitor
Triple therapy
Online Access:https://doi.org/10.1186/s12957-025-03767-5
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items